Tag:
AMAG Pharmaceuticals
Latest Headlines
Latest Headlines
European committee backs AZ, BMS and Novartis drugs for approval
Several drug companies received nods of support for getting their prized drugs approved for the European market.
AMAG shares spike on CEO's resignation, layoff plans
The beleaguered CEO of AMAG Pharmaceuticals ( $AMAG ) took his final bow on Friday, resigning from the company as the developer announced plans to ax a quarter of its workforce and start reviewing all
AMAG Pharma shareholders shoot down Allos buyout
After many criticisms of its plans, AMAG Pharmaceuticals ($AMAG) failed to get shareholder support today in their vote on the company's proposed buyout of Allos Therapeutics in a deal valued at
AMAG investor out to derail Allos merger with buyout offer
A few days ago AMAG Pharmaceuticals raised eyebrows with its proposed merger with Allos Therapeutics. The two companies didn't have much in common, aside from disappointing sales of two very
AMAG and Allos to merge, readying the budget axe
AMAG Pharmaceuticals ( $AMAG ) and Allos Therapeutics ( $ALTH ) struck a deal to merge in an all-stock transaction valued at $686 million. And the two developers have already identified $55 million to
AMAG Pharma opts for cloud over internal infrastructure
AMAG Pharmaceuticals , since 2009, has prohibited internal lines of business from buying any kind of software but SaaS. IT director Nathan McBride "wants to get the entire company to the cloud as soon
AMAG to cut staff by 24%, reports safety issues for kidney drug
Lexington, MA-based AMAG Pharmaceuticals said today that 146 cases of serious adverse events have been reported in patients taking Feraheme, a recently-approved drug for iron deficiency anemia in
Will looming drug approval make AMAG a buyout target?
After nearly three decades of drug development work, AMAG Pharmaceuticals appears poised to gain an FDA approval for its first product. And a group of analysts have been providing the company with a
AMAG shares slump on new FDA letter
Shares of AMAG Pharmaceuticals plunged 20 percent after the company announced its second FDA response letter for its experimental anemia drug ferumoxytol. Regulators want more information on
FDA delays approval of AMAG anemia drug
Shares of AMAG Pharmaceuticals were dinged by the news that the FDA is asking for more information on its experimental anemia drug ferumoxytol. The stock slid 13 percent after the company announced
